BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers

Reuters

27 Mar

BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers

March 27 (Reuters) - Chemomab Therapeutics Ltd CMMB.O:

CHEMOMAB REPORTS POSITIVE RESULTS IN NEBOKITUG PHASE 2 PSC OPEN LABEL EXTENSION TRIAL SHOWING CONTINUED BROAD AND SUBSTANTIAL IMPROVEMENTS IN KEY LIVER BIOMARKERS
CHEMOMAB THERAPEUTICS LTD - TREATMENT FOR UP TO 48 WEEKS WAS WELL-TOLERATED
CHEMOMAB THERAPEUTICS- REINFORCES AND EXPANDS POSITIVE RESULTS FROM 15-WEEK DOUBLE-BLIND PHASE 2 SPRING TRIAL

Source text: ID:nGNXbPbd3d

Further company coverage: CMMB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522370225"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522370225\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522370225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522370225","market":"nz","top_or_hot":-1,"title":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers</title></head><body><p><span>March 27 (Reuters)</span><span> - </span>Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>CMMB.O</span>:</p><ul><li><p>CHEMOMAB REPORTS POSITIVE RESULTS IN NEBOKITUG PHASE 2 PSC OPEN LABEL EXTENSION TRIAL SHOWING CONTINUED BROAD AND SUBSTANTIAL IMPROVEMENTS IN KEY LIVER BIOMARKERS</p></li><li><p>CHEMOMAB THERAPEUTICS LTD - TREATMENT FOR UP TO 48 WEEKS WAS WELL-TOLERATED</p></li><li><p>CHEMOMAB THERAPEUTICS- REINFORCES AND EXPANDS POSITIVE RESULTS FROM 15-WEEK DOUBLE-BLIND PHASE 2 SPRING TRIAL</p></li></ul><p>Source text: <span>ID:nGNXbPbd3d</span></p><p>Further company coverage: <span>CMMB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-27 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers</title></head><body><p><span>March 27 (Reuters)</span><span> - </span>Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>CMMB.O</span>:</p><ul><li><p>CHEMOMAB REPORTS POSITIVE RESULTS IN NEBOKITUG PHASE 2 PSC OPEN LABEL EXTENSION TRIAL SHOWING CONTINUED BROAD AND SUBSTANTIAL IMPROVEMENTS IN KEY LIVER BIOMARKERS</p></li><li><p>CHEMOMAB THERAPEUTICS LTD - TREATMENT FOR UP TO 48 WEEKS WAS WELL-TOLERATED</p></li><li><p>CHEMOMAB THERAPEUTICS- REINFORCES AND EXPANDS POSITIVE RESULTS FROM 15-WEEK DOUBLE-BLIND PHASE 2 SPRING TRIAL</p></li></ul><p>Source text: <span>ID:nGNXbPbd3d</span></p><p>Further company coverage: <span>CMMB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMMB","symbol_name":"Chemomab Therapeutics Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:1","article_id":"2522370225","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522370225","pubTimestamp":1743078761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver BiomarkersMarch 27 (Reuters) - Chemomab Th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMMB":"Chemomab Therapeutics Ltd.","BK4139":"生物科技"},"translate_title":"BRIEF-Chemomab报告nebokitug 2期PSC开放标签扩展试验的积极结果，显示关键肝脏生物标志物持续广泛和实质性改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMMB":0.9},"content_text":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver BiomarkersMarch 27 (Reuters) - Chemomab Therapeutics Ltd CMMB.O:CHEMOMAB REPORTS POSITIVE RESULTS IN NEBOKITUG PHASE 2 PSC OPEN LABEL EXTENSION TRIAL SHOWING CONTINUED BROAD AND SUBSTANTIAL IMPROVEMENTS IN KEY LIVER BIOMARKERSCHEMOMAB THERAPEUTICS LTD - TREATMENT FOR UP TO 48 WEEKS WAS WELL-TOLERATEDCHEMOMAB THERAPEUTICS- REINFORCES AND EXPANDS POSITIVE RESULTS FROM 15-WEEK DOUBLE-BLIND PHASE 2 SPRING TRIALSource text: ID:nGNXbPbd3dFurther company coverage: CMMB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}